“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
New client – content coming soon.
Healthcare
Healthcare
Managing Director - Head of Content, Healthcare
Claus Frisenberg Pedersen
CFO
Neil Goldsmith
Chairman
Peter Buhl Jensen
CEO
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 8.1 | 8.1 | (95.6) |
| Relative | 10.4 | 9.5 | (95.8) |
| 52 week high/low | SEK35.0/SEK0.5 |
RhoVac’s Phase IIb BRaVac trial has been fully enrolled since September 2021. According to the latest guidance, key results are expected in May or June 2022, which is the most significant catalyst of the investment case so far. The BRaVac trial is investigating RV001, a tissue-agnostic cancer immunotherapy now known as onilcamotide, in prostate cancer patients with localised disease who have relapsed after treatment with curative intent. There is a lack of treatment options in this stage and patients would typically be offered a ‘watchful waiting’ approach even though there already are signs of the cancer reappearing, so the unmet need is high. Our valuation has increased slightly to SEK1.71bn or SEK89.5/share (from SEK84.9/share previously) after rolling the model forward.
Get access to the very latest content matched to your personal investment style.
